BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 21925733)

  • 1. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
    Brown J; Brown KA; Forrest A
    Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
    Brown J; Brown K; Forrest A
    Antimicrob Agents Chemother; 2012 Feb; 56(2):634-8. PubMed ID: 22123681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis.
    Bhavnani SM; Prakhya A; Hammel JP; Ambrose PG
    Clin Infect Dis; 2009 Sep; 49(5):691-8. PubMed ID: 19635023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
    Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R; Davis SL; Levine DP; Rybak MJ
    Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin].
    Rubio-Terrés C; Rubio-Rodríguez D; Majos N; Grau S
    Rev Esp Quimioter; 2012 Dec; 25(4):283-92. PubMed ID: 23303261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.
    Joo J; Yamaki J; Lou M; Hshieh S; Chu T; Shriner KA; Wong-Beringer A
    Clin Ther; 2013 Jul; 35(7):995-1004. PubMed ID: 23829982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia?
    de Sanctis JT; Swami A; Sawarynski K; Gerasymchuk L; Powell K; Robinson-Dunn B; Carpenter CF; Sims MD
    Diagn Mol Pathol; 2011 Sep; 20(3):184-8. PubMed ID: 21817905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study.
    Chang HJ; Hsu PC; Yang CC; Siu LK; Kuo AJ; Chia JH; Wu TL; Huang CT; Lee MH
    J Antimicrob Chemother; 2012 Mar; 67(3):736-41. PubMed ID: 22169187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
    Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME
    Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH
    Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
    Casapao AM; Davis SL; McRoberts JP; Lagnf AM; Patel S; Kullar R; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4636-41. PubMed ID: 24890596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.
    Kopp BJ; Nix DE; Armstrong EP
    Ann Pharmacother; 2004 Sep; 38(9):1377-82. PubMed ID: 15266044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
    Ruggero MA; Peaper DR; Topal JE
    Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
    Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
    Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
    Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
    Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.